| Current Price | $10.68 | Mkt Cap | $542.4M |
|---|---|---|---|
| Open | $11.19 | P/E Ratio | 0.00 |
| Prev. Close | $10.68 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $10.51 - $11.46 | Volume | 800,635 |
| 52-Wk Range | $10.51 - $15.07 | Avg. Daily Vol. | 1,465,328 |
| Current Price | $10.68 | Mkt Cap | $542.4M |
|---|---|---|---|
| Open | $11.19 | P/E Ratio | 0.00 |
| Prev. Close | $10.68 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $10.51 - $11.46 | Volume | 800,635 |
| 52-Wk Range | $10.51 - $15.07 | Avg. Daily Vol. | 1,465,328 |
The best Bull and Bear pitches based on recency and number of recommendations.
From 06/11/19:"Investors interested in the potential of gene editing to significantly affect human healthcare might want to give Precision BioSciences a closer look. The business owns a proprietary platform that avoids some of the primary concerns… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about DTIL.
Recs
TMFBlacknGold
(96.65)
Submitted: 11/22/2019 11:52:22 AM :
Start Price:
$6.40
NASDAQ:DTIL Score:
+55.94
From 06/11/19:
"Investors interested in the potential of gene editing to significantly affect human healthcare might want to give Precision BioSciences a closer look. The business owns a proprietary platform that avoids some of the primary concerns with CRISPR gene editing. And although ARCUS gene editing shares one key disadvantage with CRISPR, the company strategically focused initial clinical programs on allogeneic immunotherapies, which should give it a leg up in the competitive -- and potentially lucrative -- race. Throw in a unique pipeline in agricultural applications and sprinkle in the fact the company is flush with cash, and the $680 million gene-editing upstart might be worth the wait for long-term investors."
https://www.fool.com/investing/2019/06/11/is-the-newest-gene-editing-stock-a-buy.aspx
Recs
MattK520
(72.65)
Submitted: 3/28/2019 11:30:05 AM :
Start Price:
$18.00
NASDAQ:DTIL Score:
-59.11
Revolutionary gene editing technology, alternative to CRISPR
Find the members with the highest scoring picks in DTIL.
bonjourmesamis (76.13) Score: +65.77
The Score Leader is the player with the highest score across all their picks in DTIL.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| Smiley81 | < 20 | 10/28/2019 |
|
5Y | $6.30 | +69.52% | +9.61% | +59.91 | 0 Comment | |
| odocoileus | 28.13 | 10/24/2019 |
|
5Y | $6.33 | +68.85% | +10.63% | +58.23 | 0 Comment | |
| TMFBlacknGold | 96.65 | 10/23/2019 |
|
5Y | $6.40 | +67.01% | +11.06% | +55.94 | 1 Comment | |
| IPO2019 | 36.95 | 9/9/2019 |
|
5Y | $8.12 | +31.53% | +11.28% | +20.25 | 0 Comment | |
| Paco57 | 24.39 | 11/14/2019 |
|
5Y | $9.55 | +11.83% | +7.53% | +4.30 | 0 Comment | |
| theoutline | 64.47 | 12/16/2019 |
|
3Y | $10.40 | +2.69% | +4.02% | -1.33 | 0 Comment | |
| iheadhunt | 72.25 | 7/24/2019 |
|
5Y | $12.78 | -16.43% | +10.75% | -27.19 | 0 Comment | |
| cheev | 99.97 | 6/18/2019 |
|
5Y | $12.64 | -15.51% | +13.53% | -29.03 | 0 Comment | |
|
biznessdoc | 63.75 | 7/22/2019 |
|
5Y | $13.94 | -23.39% | +11.57% | -34.96 | 0 Comment |
| bckearns | 78.74 | 11/26/2019 |
|
5Y | $16.50 | -35.27% | +5.87% | -41.15 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
